This combined strategy has been effective and safe in treating several refractory solid tumors, such as non-small cell lung cancer post-EGFR-TKI resistance, extensive-stage small cell lung cancer, and advanced cervical cancer [e.g., IMpower151, ORIENT31 (26), ETER701 (27), HARMONi-A (28), and BEATcc (29)]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.